explore -WSS

explore

author：knowledge 2025-09-28 17:41:47 Page View：45

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New oral drug delivery patch is modeled after octopus tentacles
Next article： Jerome Adams on the need for new antivirals for Covid

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

The biotech scorecard for Q4: 16 stock

RyanPierse/GettyImagesHereisSTAT’sbiotechscorecard,ourregularledgerofstock-movingbiotechevents,forth

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Some top drug companies are starting to take action on climate

AdobeThisarticleisadaptedfromSTAT’sexclusiveanalysisintheSTATReport: “Climaterankings:Howtopdrugcomp